vergentbio 品牌介绍
品牌简介
实体肿瘤手术切除过程中，完全切除肿瘤边缘残留癌与提高治愈率密切相关，但即使是经验丰富的外科医生，也往往难以区分癌组织与正常组织。视觉分化需要在细胞水平。
我们的分子靶向探针与肿瘤组织中过表达的酶结合，激活一种明亮的荧光染料。这种专利探针可以识别和绑定多种癌症，包括肺癌、乳腺癌、卵巢癌、结肠直肠癌和脑癌等。当在手术前注射这种探针时，它会“点亮”癌组织，并为手术提供清晰的视觉指导。
Vergent的方法直接解决了开放、腹腔镜和机器人手术中先进可视化技术的临床需求和市场机会，同时独特地保留了价值导向医疗系统中成功所需的定价灵活性
Targeting cancer through enhanced tumor visualization
While the complete removal of residual cancer at the tumor margins during the surgical resection of solid tumors is closely linked with improved cure rates, it is often difficult for even experienced surgeons to distinguish cancerous tissue from normal tissue. Visual differentiation is needed at the cellular level.
Our molecularly-targeted probe binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary probe can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, the probe “lights up” cancerous tissue and gives the surgeon a clear visual guide for the removal procedure.
Vergent’s approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system
Main product
Targeting cancer through
enhanced tumor
visualization
http://www.vergentbio.com
联系我们
